Full-time · Global
Who We Are
Cogent Biosciences is a publicly traded biotechnology company developing real solutions to treat genetically driven diseases. With a focus on rational drug discovery and development, we are leveraging validated biology to advance precision therapies designed to address the true underlying drivers of disease and provide real hope for patients. Cogent’s lead therapeutic candidate, bezuclastinib (CGT9486), is a precision kinase inhibitor designed to selectively and potently inhibit the KIT D816V mutation. This mutation is responsible for driving a rare and serious condition called Systemic Mastocytosis (SM), which can severely impact many different tissues and organs in the body. We are also studying CGT9486 to treat advanced gastrointestinal stromal tumors (GIST), which have a strong dependence on oncogenic KIT signaling. We are currently enrolling two Phase 2 clinical trials for patients with SM and a global Phase 3 trial for GIST patients.
Our Team
https://cogent.culturehq.com/
Job Summary: Cogent Biosciences is growing! This position plays a crucial role within the company representing quality on development projects for Cogent Bioscience therapies. The ideal candidate will have a strong understanding of cGMPs, FDA and ICH guidance, and excellent writing abilities. They would have a seat at the table where they could intellectually contribute and work with a multi-disciplinary team with the common goal of bringing forward innovative cancer therapies.
What You Will Do:
What You Bring:
Open roles at Cogent Biosciences